AYTU BIOPHARMA, INC Cost of Revenue
AYTU BIOPHARMA, INC (AYTU) reported Cost of Revenue of $9.99 million for the 3-month period ending 2023-03-31, per its 10-Q filed 2023-05-11.
Discontinued › Expense Statement
us-gaap:CostOfRevenue · last filed 2023-05-11
- AYTU BIOPHARMA, INC cost of revenue for the quarter ending 2023-03-31 was $9.99M, a 13.23% decline year-over-year.
- AYTU BIOPHARMA, INC cost of revenue for the quarter ending 2022-12-31 was $8.99M, a 17.00% decline year-over-year.
- AYTU BIOPHARMA, INC cost of revenue for the quarter ending 2022-09-30 was $9.62M, a 1.93% increase year-over-year.
- AYTU BIOPHARMA, INC cost of revenue for the quarter ending 2022-06-30 was $12.61M, a 3.47% increase year-over-year.
- AYTU BIOPHARMA, INC cost of revenue for fiscal 2022 was $44.39M, a 21.83% increase from fiscal 2021.
- AYTU BIOPHARMA, INC cost of revenue for fiscal 2021 was $36.43M, a 339.95% increase from fiscal 2020.
- AYTU BIOPHARMA, INC cost of revenue for fiscal 2020 was $8.28M, a 276.06% increase from fiscal 2019.
- AYTU BIOPHARMA, INC cost of revenue for fiscal 2019 was $2.20M, a 7.39% increase from fiscal 2018.
| Period end | Cost of Revenue 3 month | Cost of Revenue 3 month as first filed | Cost of Revenue 6 month | Cost of Revenue 6 month as first filed | Cost of Revenue 9 month | Cost of Revenue 9 month as first filed | Cost of Revenue 12 month | Cost of Revenue 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2023-03-31 | $9.99M 10-Q · filed 2023-05-11 | $18.98M derived: sum of 2 quarters · filed 2023-05-11 | $28.60M 10-Q · filed 2023-05-11 | $41.20M derived: sum of 4 quarters · filed 2023-05-11 | ||||
| 2022-12-31 | $8.99M 10-Q · filed 2023-02-21 | $18.61M 10-Q · filed 2023-02-21 | $31.21M derived: sum of 3 quarters · filed 2023-02-21 | $42.73M derived: sum of 4 quarters · filed 2023-05-11 | ||||
| 2022-09-30 | $9.62M 10-Q/A · filed 2023-02-21 | $22.23M derived: sum of 2 quarters · filed 2023-02-21 | $33.74M derived: sum of 3 quarters · filed 2023-05-11 | $44.57M derived: sum of 4 quarters · filed 2023-05-11 | ||||
| 2022-06-30 | $12.61M derived: 10-K 12 month − 10-Q 9 month · filed 2022-09-27 | $24.12M derived: sum of 2 quarters · filed 2023-05-11 | $34.95M derived: sum of 3 quarters · filed 2023-05-11 | $44.39M 10-K · filed 2022-09-27 | ||||
| 2022-03-31 | $11.51M 10-Q · filed 2023-05-11 | $22.34M derived: sum of 2 quarters · filed 2023-05-11 | $31.78M 10-Q · filed 2023-05-11 | $43.96M derived: sum of 4 quarters · filed 2023-05-11 | ||||
| 2021-12-31 | $10.83M 10-Q · filed 2023-02-21 | $20.27M 10-Q · filed 2023-02-21 | $32.45M derived: sum of 3 quarters · filed 2023-02-21 | $46.38M derived: sum of 4 quarters · filed 2023-02-21 | ||||
| 2021-09-30 | $9.44M 10-Q/A · filed 2023-02-21 | $21.62M derived: sum of 2 quarters · filed 2023-02-21 | $35.56M derived: sum of 3 quarters · filed 2023-02-21 | $41.81M derived: sum of 4 quarters · filed 2023-02-21 | ||||
| 2021-06-30 | $12.18M derived: 10-K 12 month − 10-Q 9 month · filed 2022-09-27 | $26.12M derived: sum of 2 quarters · filed 2022-09-27 | $32.37M derived: sum of 3 quarters · filed 2022-09-27 | $36.43M 10-K · filed 2022-09-27 | ||||
| 2021-03-31 | $13.94M 10-Q · filed 2022-05-16 | $13.68M 10-Q · filed 2021-05-17 | $20.19M derived: sum of 2 quarters · filed 2022-05-16 | $24.25M 10-Q · filed 2022-05-16 | $23.50M 10-Q · filed 2021-05-17 | $29.55M derived: sum of 4 quarters · filed 2022-05-16 | ||
| 2020-12-31 | $6.25M 10-Q · filed 2022-02-14 | $6.00M 10-Q · filed 2021-02-11 | $10.31M 10-Q · filed 2022-02-14 | $9.82M 10-Q · filed 2021-02-11 | $15.61M derived: sum of 3 quarters · filed 2022-02-14 | $17.61M derived: sum of 4 quarters · filed 2022-02-14 | ||
| 2020-09-30 | $4.06M 10-Q · filed 2021-11-15 | $3.82M 10-Q · filed 2020-11-12 | $9.36M derived: sum of 2 quarters · filed 2021-11-15 | $11.36M derived: sum of 3 quarters · filed 2021-11-15 | $11.97M derived: sum of 4 quarters · filed 2021-11-15 | |||
| 2020-06-30 | $5.30M derived: 10-K 12 month − 10-Q 9 month · filed 2021-09-28 | $7.30M derived: sum of 2 quarters · filed 2021-09-28 | $7.91M derived: sum of 3 quarters · filed 2021-09-28 | $8.28M 10-K · filed 2021-09-28 | $7.55M 10-K · filed 2020-10-06 | |||
| 2020-03-31 | $2.00M 10-Q · filed 2021-05-17 | $2.60M derived: sum of 2 quarters · filed 2021-05-17 | $2.98M 10-Q · filed 2021-05-17 | $3.63M derived: sum of 4 quarters · filed 2021-05-17 | ||||
| 2019-12-31 | $606.05K 10-Q · filed 2021-02-11 | $981.77K 10-Q · filed 2021-02-11 | $1.63M derived: sum of 3 quarters · filed 2021-02-11 | $2.25M derived: sum of 4 quarters · filed 2021-02-11 | ||||
| 2019-09-30 | $375.72K 10-Q · filed 2020-11-12 | $1.02M derived: sum of 2 quarters · filed 2020-11-12 | $1.64M derived: sum of 3 quarters · filed 2020-11-12 | $2.17M derived: sum of 4 quarters · filed 2020-11-12 | ||||
| 2019-06-30 | $649.09K derived: 10-K 12 month − 10-Q 9 month · filed 2020-10-06 | $1.27M derived: sum of 2 quarters · filed 2020-10-06 | $1.79M derived: sum of 3 quarters · filed 2020-10-06 | $2.20M 10-K · filed 2020-10-06 | ||||
| 2019-03-31 | $616.85K 10-Q · filed 2020-05-15 | $1.14M derived: sum of 2 quarters · filed 2020-05-15 | $1.55M 10-Q · filed 2020-05-15 | $1.79M derived: sum of 4 quarters · filed 2020-05-15 | ||||
| 2018-12-31 | $525.14K 10-Q · filed 2020-02-14 | $936.10K 10-Q · filed 2020-02-14 | $1.18M derived: sum of 3 quarters · filed 2020-02-14 | $2.31M derived: sum of 4 quarters · filed 2020-02-14 | ||||
| 2018-09-30 | $410.96K 10-Q · filed 2019-11-14 | $652.06K derived: sum of 2 quarters · filed 2019-11-14 | $1.79M derived: sum of 3 quarters · filed 2019-11-14 | $2.17M derived: sum of 4 quarters · filed 2019-11-14 | ||||
| 2018-06-30 | $241.10K derived: 10-K 12 month − 10-Q 9 month · filed 2019-09-26 | $1.38M derived: sum of 2 quarters · filed 2019-09-26 | $1.76M derived: sum of 3 quarters · filed 2019-09-26 | $2.05M 10-K · filed 2019-09-26 | ||||
| 2018-03-31 | $1.14M 10-Q · filed 2019-05-14 | $1.52M derived: sum of 2 quarters · filed 2019-05-14 | $1.81M 10-Q · filed 2019-05-14 | $2.16M derived: sum of 4 quarters · filed 2019-05-14 | ||||
| 2017-12-31 | $385.41K 10-Q · filed 2019-05-14 | $672.61K 10-Q · filed 2019-05-14 | $1.02M derived: sum of 3 quarters · filed 2019-05-14 | $1.35M derived: sum of 4 quarters · filed 2019-05-14 | ||||
| 2017-09-30 | $287.20K 10-Q · filed 2018-11-07 | $636.90K derived: sum of 2 quarters · filed 2018-11-07 | $961.34K derived: sum of 3 quarters · filed 2018-11-07 | $1.51M derived: sum of 4 quarters · filed 2018-11-07 | ||||
| 2017-06-30 | $349.70K derived: 10-K 12 month − 10-Q 9 month · filed 2018-09-06 | $674.14K derived: sum of 2 quarters · filed 2018-09-06 | $1.23M derived: sum of 3 quarters · filed 2018-09-06 | $1.42M 10-K · filed 2018-09-06 | ||||
| 2017-03-31 | $324.44K 10-Q · filed 2018-05-14 | $875.73K derived: sum of 2 quarters · filed 2018-05-14 | $1.07M 10-Q · filed 2018-05-14 | $1.40M derived: sum of 4 quarters · filed 2018-05-14 | ||||
| 2016-12-31 | $551.29K 10-Q · filed 2018-02-08 | $743.22K 10-Q · filed 2018-02-08 | $1.08M derived: sum of 3 quarters · filed 2018-02-08 | $1.42M derived: sum of 4 quarters · filed 2018-02-08 | ||||
| 2016-09-30 | $191.92K 10-Q · filed 2017-11-09 | $526.78K derived: sum of 2 quarters · filed 2017-11-09 | $867.57K derived: sum of 3 quarters · filed 2017-11-09 | $1.11M derived: sum of 4 quarters · filed 2017-11-09 | ||||
| 2016-06-30 | $334.85K derived: 10-K 12 month − 10-Q 9 month · filed 2017-08-31 | $675.65K derived: sum of 2 quarters · filed 2017-08-31 | $919.75K derived: sum of 3 quarters · filed 2017-08-31 | $957.08K 10-K · filed 2017-08-31 | ||||
| 2016-03-31 | $340.80K 10-Q · filed 2017-05-11 | $584.90K derived: sum of 2 quarters · filed 2017-05-11 | $622.22K 10-Q · filed 2017-05-11 | $710.33K derived: sum of 4 quarters · filed 2017-05-11 | ||||
| 2015-12-31 | $244.10K 10-Q · filed 2017-02-09 | $281.43K 10-Q · filed 2017-02-09 | $369.53K derived: sum of 3 quarters · filed 2017-02-09 | $369.53K derived: sum of 4 quarters · filed 2017-02-09 | ||||
| 2015-09-30 | $37.33K 10-Q · filed 2016-11-07 | $125.43K derived: sum of 2 quarters · filed 2016-11-07 | $125.43K derived: sum of 3 quarters · filed 2016-11-07 | $125.43K derived: sum of 4 quarters · filed 2016-11-07 | ||||
| 2015-06-30 | $88.11K derived: 10-K 12 month − 10-Q 9 month · filed 2016-09-01 | $88.11K derived: sum of 2 quarters · filed 2016-09-01 | $88.11K derived: sum of 3 quarters · filed 2016-09-01 | $88.11K 10-K · filed 2016-09-01 | ||||
| 2015-03-31 | $0.00 10-Q · filed 2016-05-11 | $0.00 derived: sum of 2 quarters · filed 2016-05-11 | $0.00 10-Q · filed 2016-05-11 | |||||
| 2014-12-31 | $0.00 10-Q · filed 2016-02-11 | $225.00 10-Q · filed 2016-02-11 | ||||||
| 2014-09-30 | $225.00 10-Q · filed 2015-11-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |